Citations

Showing 10 of 108094 citations.

Preoperative Localization of Recurrence in the Thyroidectomy Bed Using a Radioactive Iodine125 Seed
Garner, Hillary W. , Paz‐Fumagalli, Ricardo , Young, Geoffrey D., Garner, Hillary W

Mayo Clinic

Otolaryngology–Head and Neck Surgery | April 24, 2018 | Volume: 159 | Issue: 2 | Pages: 394-397

10.1177/0194599818772049 | PMID 29685086 Get It

Intraoperative localization of nonpalpable recurrent thyroid cancer has been reported using needle localization, intraoperative ultrasound (US), dye injection, and radio‐guided surgery. We describe the alternative technique of radioactive seed localization (RSL) in 3 patients with residual or recurrent papillary thyroid cancer. This technique has been used for many years in the setting of nonpalpable breast cancer, where it has been shown to be safe and has been associated with greater surgeon satisfaction as well as improved patient tolerability, cosmesis, and outcomes compared to needle localization. In addition, RSL allows complete decoupling of the radiology and surgery schedules. RSL was successful in our 3 patients with regard to safety, patient tolerability, and scheduling.
Extrapolating the Limits of the Nasoseptal Flap With Pedicle Dissection to the Internal Maxillary Artery
Pinheiro‐Neto, Carlos , Peris‐Celda, Maria , Kenning, Tyler, Pinheiro-Neto, Carlos D

Mayo Clinic

Operative Neurosurgery | April 24, 2018 | Volume: 16 | Issue: 1 | Pages: 37-44

10.1093/ons/opy075 | PMID 29688445 Get It

Abstract BACKGROUND The nasoseptal flap is the main pedicled flap used for endoscopic cranial base reconstruction. For large anterior cranial base defects, the anterior edge is a concern for the nasoseptal flap reach. OBJECTIVE To present a surgical technique that completely releases the vascular pedicle of the nasoseptal flap from the sphenopalatine artery (SPA) foramen improving considerably the reach of the flap. METHODS A patient with left anterior cranial base fracture involving the posterior table of the frontal sinus, who presented with cerebrospinal fluid leak and contused brain herniation to the ethmoid and frontal sinuses. Unilateral endoscopic endonasal anterior cranial base reconstruction was performed with left sided nasoseptal flap. The nasoseptal flap pedicle was dissected and completely released from the SPA foramen. The flap was left attached only to the internal maxillary artery (IMAX) vascular bundle. RESULTS The flap covered the entire left anterior cranial base, from the planum sphenoidale to the posterior table of the frontal sinus. There was complete obliteration of the cerebrospinal fluid fistula postoperatively with resolution of the radiographic pneumocephalus and the patient's rhinorrhea. CONCLUSION The complete release of the nasoseptal flap pedicle from the SPA foramen is feasible and remarkably improves the reach of the flap. It also increases the reconstructive area of the flap since the entire septal mucosa can be used for reconstruction and the pedicle length is based exclusively upon the SPA/IMAX.
Revascularization for Left Main and Multivessel Coronary Artery Disease: Current Status and Future Prospects after the EXCEL and NOBLE Trials
Al‐Hijji, Mohammed , Sabbagh, Abdallah El , Holmes, David R. , El Sabbagh, Abdallah , Al-Hijji, Mohammed A

Mayo Clinic

Korean Circulation Journal | April 24, 2018 | Volume: 48 | Issue: 6 | Pages: 447

10.4070/kcj.2018.0078 | PMID 29856140 Get It

Comment on 2018 American Academy of Neurology guidelines on disease-modifying therapies in MS
Weinshenker, Brian G. , Wingerchuk, Dean M. , Corboy, John R. , Weinshenker, Brian G

Mayo Clinic

Neurology | April 23, 2018 | Volume: 90 | Issue: 24 | Pages: 1106-1112

10.1212/wnl.0000000000005574 | PMID 29685920 Get It

Predicting Outcomes in Idiopathic Pulmonary Fibrosis Using Automated Computed Tomographic Analysis
Jacob, Joseph , Bartholmai, Brian J. , Rajagopalan, Srinivasan, Moorsel, Coline H.M. van , Es, Hendrik W. van, Beek, Frouke T. van, Struik, Marjolijn H. L., Kokosi, Maria , Egashira, Ryoko , Brun, Anne‐Laure , Nair, Arjun , Walsh, Simon , Cross, Gary , Barnett, Joseph , Lauretis, Angelo De, Judge, Eoin P., Desai, Sujal R. , Karwoski, Ronald A., Ourselin, Sébastien , Renzoni, Elisabetta , Maher, Toby M. , Altmann, André , Wells, Athol U. , Karwoski, Ronald, Bartholmai, Brian J , Maher, Toby , Egashira, Ryoko

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 23, 2018 | Volume: 198 | Issue: 6 | Pages: 767-776

10.1164/rccm.201711-2174oc | PMID 29684284 Get It

Abstract Rationale Quantitative computed tomographic (CT) measures of baseline disease severity might identify patients with idiopathic pulmonary fibrosis (IPF) with an increased mortality risk. We evaluated whether quantitative CT variables could act as a cohort enrichment tool in future IPF drug trials. Objectives To determine whether computer-derived CT measures, specifically measures of pulmonary vessel–related structures (VRSs), can better predict functional decline and survival in IPF and reduce requisite sample sizes in drug trial populations. Methods Patients with IPF undergoing volumetric noncontrast CT imaging at the Royal Brompton Hospital, London, and St. Antonius Hospital, Utrecht, were examined to identify pulmonary function measures (including FVC) and visual and computer-derived (CALIPER [Computer-Aided Lung Informatics for Pathology Evaluation and Rating] software) CT features predictive of mortality and FVC decline. The discovery cohort comprised 247 consecutive patients, with validation of results conducted in a separate cohort of 284 patients, all fulfilling drug trial entry criteria. Measurements and Main Results In the discovery and validation cohorts, CALIPER-derived features, particularly VRS scores, were among the strongest predictors of survival and FVC decline. CALIPER results were accentuated in patients with less extensive disease, outperforming pulmonary function measures. When used as a cohort enrichment tool, a CALIPER VRS score greater than 4.4% of the lung was able to reduce the requisite sample size of an IPF drug trial by 26%. Conclusions Our study has validated a new quantitative CT measure in patients with IPF fulfilling drug trial entry criteria—the VRS score—that outperformed current gold standard measures of outcome. When used for cohort enrichment in an IPF drug trial setting, VRS threshold scores can reduce a required IPF drug trial population size by 25%, thereby limiting prohibitive trial costs. Importantly, VRS scores identify patients in whom antifibrotic medication prolongs life and reduces FVC decline.
Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis
Shah, Nirav N. , Ahn, Kwang Woo , Litovich, Carlos, Fenske, Timothy S. , Ahmed, Sairah , Bejanyan, Nelli , Bolaños‐Meade, Javier , Chen, Andy I. , Ciurea, Stefan O. , Bachanová, Veronika , DeFilipp, Zachariah , Epperla, Narendranath , Farhadfar, Nosha , Herrera, Alex F. , Haverkos, Bradley M. , Holmberg, Leona , Hossain, Nasheed , Kharfan‐Dabaja, Mohamed A. , Kenkre, Vaishalee P. , Murthy, Hemant S. , Rezvani, Andrew R. , D’Souza, Anita , Ulrickson, Matthew L. , Waller, Edmund K. , Sureda, Anna , Smith, Sonali M. , Holmberg, Leona , Chen, Andy , Kharfan-Dabaja, Mohamed A., D'Souza, Anita , Bachanova, Veronika , Murthy, Hemant S , Waller, Edmund K , Epperla, Narendranath , Ahmed, Sairah , Battiwalla, Minoo , Dahi, Parastoo B , Lazarus, Hillard M. , Nishihori, Taiga , Savani, Bipin N. , Hamadani, Mehdi

Mayo Clinic

Blood Advances | April 23, 2018 | Volume: 2 | Issue: 8 | Pages: 933-940

10.1182/bloodadvances.2018018531 | PMID 29685953 Get It

Key Points There was no difference in overall survival after allogeneic transplant between patients aged 55-64 years and patients ≥65 years. Age alone should not be a determinant for allogeneic transplant eligibility among older non-Hodgkin lymphoma patients.
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort
Stahl, Maximilian , DeVeaux, Michelle, Montesinos, Pau , Itzykson, Raphaël , Ritchie, Ellen K. , Sekeres, Mikkael A. , Brunner, Andrew M. , Komrokji, Rami S. , Bhatt, Vijaya Raj , Al‐Kali, Aref , Cluzeau, Thomas , Santini, Valeria , Fathi, Amir T. , Fenaux, Pierre , Litzow, Mark R. , Kim, Tae Kon , Vey, Norbert , Germing, Ulrich, Bergua, Juan , Gore, Steven D. , Zeidan, Amer M. , Komrokji, Rami S , Bergua, Juan Miguel , Sekeres, Mikkael A , Montesinos, Pau , Bhatt, Vijaya Raj , Itzykson, Raphael , Santini, Valeria , Kim, Tae Kon , Barnard, John , Podoltsev, Nikolai , Roboz, Gail J. , Perreault, Sarah , Prébet, Thomas , Verma, Vivek , Germing, Ulrich , Serrano, Josefina , Zeidan, Amer M

Mayo Clinic

Blood Advances | April 23, 2018 | Volume: 2 | Issue: 8 | Pages: 923-932

10.1182/bloodadvances.2018016121 | PMID 29685952 Get It

Key Points In the largest study of HMAs in RR-AML to date, 16% of patients achieved CR/CRi and experienced a median OS of 21 months. Low proliferative disease (peripheral blood blasts <5%) was associated with improved response and OS.
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Joseph, Richard W. , Elassaiss‐Schaap, Jeroen , Kefford, Richard , Hwu, Wen-Jen , Joshua, Anthony M. , Ribas, Antoni , Hodi, F. Stephen , Hamid, Omid , Robert, Caroline , Daud, Adil , Dronca, Roxana , Hersey, Peter , Weber, Jeffrey S. , Patnaik, Amita , Alwis, Dinesh P. de, Perrone, Andrea , Zhang, Jin , Kang, Soonmo Peter, Ebbinghaus, Scot, Anderson, Keaven M. , Gangadhar, Tara C., Daud, Adil I , Hwu, Wen‐Jen , Wolchok, Jedd D. , Weber, Jeffrey

Mayo Clinic

Clinical Cancer Research | April 23, 2018 | Volume: 24 | Issue: 20 | Pages: 4960-4967

10.1158/1078-0432.ccr-17-2386 | PMID 29685882 Get It

Abstract Purpose: The purpose of this study was to assess the association of baseline tumor size (BTS) with other baseline clinical factors and outcomes in pembrolizumab-treated patients with advanced melanoma in KEYNOTE-001 (NCT01295827). Experimental Design: BTS was quantified by adding the sum of the longest dimensions of all measurable baseline target lesions. BTS as a dichotomous and continuous variable was evaluated with other baseline factors using logistic regression for objective response rate (ORR) and Cox regression for overall survival (OS). Nominal P values with no multiplicity adjustment describe the strength of observed associations. Results: Per central review by RECIST v1.1, 583 of 655 patients had baseline measurable disease and were included in this post hoc analysis. Median BTS was 10.2 cm (range, 1–89.5). Larger median BTS was associated with Eastern Cooperative Oncology Group performance status 1, elevated lactate dehydrogenase (LDH), stage M1c disease, and liver metastases (with or without any other sites; all P ≤ 0.001). In univariate analyses, BTS below the median was associated with higher ORR (44% vs. 23%; P &lt; 0.001) and improved OS (HR, 0.38; P &lt; 0.001). In multivariate analyses, BTS below the median remained an independent prognostic marker of OS (P &lt; 0.001) but not ORR. In 459 patients with available tumor programmed death ligand 1 (PD-L1) expression, BTS below the median and PD-L1–positive tumors were independently associated with higher ORR and longer OS. Conclusions: BTS is associated with many other baseline clinical factors but is also independently prognostic of survival in pembrolizumab-treated patients with advanced melanoma. Clin Cancer Res; 24(20); 4960–7. ©2018 AACR. See related commentary by Warner and Postow, p. 4915
Bone functional adaptation does not erase neutral evolutionary information
Agostini, Gina , Holt, Brigitte , Relethford, John H.

Mayo Clinic

American Journal of Physical Anthropology | April 23, 2018 | Volume: 166 | Issue: 3 | Pages: 708-729

10.1002/ajpa.23460 | PMID 29683479 Get It

AbstractObjectivesTo investigate whether diaphyseal and craniofacial variation similarly reflect neutral genetic variation among modern European and South Africans.Materials and methodsDiaphyseal and craniofacial data were collected on English, South European, and South African samples. The Relethford‐Blangero model was used to compare predicted among‐population relationships generated by limb bones relative to those generated by the crania and, further, to test whether adaptive plasticity affected these predicted relationships. Evidence of adaptive plasticity was confirmed by comparing J, an indicator of limb bone robusticity, among individuals who worked different occupations in industrializing Lisbon (Portugal) and Bologna (Italy).ResultsDiaphyses were more variable than were crania and more robust in individuals with physically demanding occupations—both consistent with expectations of adaptive plasticity. However, diaphyseal variation still generated among‐population relationships consistent with neutral genetic predictions and Mantel tests confirmed a high, significant correlation between diaphyseal and craniofacial distance matrices. This pattern was not strongly affected by adaptive plasticity.DiscussionAmong‐population patterns of diaphyseal variation are consistent with neutral expectations and are consistent with historical data on population composition, genetics, and migration. Furthermore, plasticity induced by Industrial‐era levels of physical activity does not erase these neutral signatures. Diaphyseal variation may therefore be useful to infer neutral (presumably genetic) information across populations, and controlling for existing relationships may strengthen inferences of physical activity made when comparing limb bone structure across populations.
VP-16, Cyclophosphamide, Adriamycin and Cis-platinum (V:CAP-I) in Patients with Metastatic Adenocarcinoma of the Lung
Eagan, Robert T., Creagan, Edward T. , Rubin, Joseph, Frytak, Stephen, Kvols, Larry K., Fleming, Thomas R. , Ingle, James N.

Mayo Clinic

Tumori Journal | April 23, 2018 | Volume: 65 | Issue: 1 | Pages: 105-109

10.1177/030089167906500112 | PMID 442215 Get It

In an attempt to improve upon the 42% regression rate of the CAP-I regimen in patients with advanced adenocarcinoma of the lung, VP-16 was added to that regimen. VP-16, as a single agent, had a response rate of 12.5% (3/24) in a similar group of patients. The new regimen, V:CAP-I, had a tumor regression rate of 35% (7/20) and an estimated median survival of 171 days. Hence, we were unable to conclude that the addition of VP-16 to the CAP-I regimen statistically improved the regression rate of the CAP-I regimen.